CY1122035T1 - Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων - Google Patents

Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων

Info

Publication number
CY1122035T1
CY1122035T1 CY20191100706T CY191100706T CY1122035T1 CY 1122035 T1 CY1122035 T1 CY 1122035T1 CY 20191100706 T CY20191100706 T CY 20191100706T CY 191100706 T CY191100706 T CY 191100706T CY 1122035 T1 CY1122035 T1 CY 1122035T1
Authority
CY
Cyprus
Prior art keywords
sdabs
directed against
compositions
against intracellular
antibodies directed
Prior art date
Application number
CY20191100706T
Other languages
Greek (el)
English (en)
Inventor
Sunanda SINGH
Original Assignee
Singh Molecular Medicine, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singh Molecular Medicine, Llc filed Critical Singh Molecular Medicine, Llc
Publication of CY1122035T1 publication Critical patent/CY1122035T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
CY20191100706T 2014-10-23 2019-07-03 Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων CY1122035T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462067908P 2014-10-23 2014-10-23
US201562148656P 2015-04-16 2015-04-16
US201562188353P 2015-07-02 2015-07-02
US201562210795P 2015-08-27 2015-08-27
PCT/US2015/057223 WO2016065323A2 (en) 2014-10-23 2015-10-23 Single domain antibodies directed against intracellular antigens

Publications (1)

Publication Number Publication Date
CY1122035T1 true CY1122035T1 (el) 2020-10-14

Family

ID=55761757

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100706T CY1122035T1 (el) 2014-10-23 2019-07-03 Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY20211101082T CY1124867T1 (el) 2014-10-23 2021-12-09 Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211101082T CY1124867T1 (el) 2014-10-23 2021-12-09 Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων

Country Status (24)

Country Link
US (4) US9546211B2 (enExample)
EP (3) EP3590962B1 (enExample)
JP (5) JP2017538671A (enExample)
KR (4) KR102207381B1 (enExample)
CN (2) CN106852148B (enExample)
AU (4) AU2015335600B2 (enExample)
BR (4) BR122020006914B8 (enExample)
CA (3) CA3052777C (enExample)
CY (2) CY1122035T1 (enExample)
DK (2) DK3590962T3 (enExample)
ES (2) ES2900253T3 (enExample)
HR (2) HRP20191056T1 (enExample)
HU (2) HUE057605T2 (enExample)
IL (2) IL289769B2 (enExample)
LT (2) LT3590962T (enExample)
MX (2) MX379450B (enExample)
PL (2) PL3590962T3 (enExample)
PT (2) PT3590962T (enExample)
RS (2) RS59063B1 (enExample)
RU (1) RU2017116710A (enExample)
SI (2) SI3590962T1 (enExample)
SM (2) SMT201900413T1 (enExample)
TW (1) TWI664289B (enExample)
WO (1) WO2016065323A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
HUE057605T2 (hu) * 2014-10-23 2022-06-28 Singh Molecular Medicine Llc Intracelluláris antigének ellen irányuló egydoménes antitestek
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
CN107454905B (zh) 2015-03-31 2023-04-28 索里索制药公司 多肽
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CN109562137A (zh) 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CN108603037B (zh) * 2015-12-10 2020-11-17 希望之城 细胞穿透花青偶联抗体
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20190076354A (ko) * 2017-12-22 2019-07-02 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물
CN111699002B (zh) 2017-12-22 2024-06-28 罗菲佰欧株式会社 抗stat3双特异性抗体及包含其的药学组合物
WO2019213481A1 (en) * 2018-05-04 2019-11-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treating inflammatory disease or disorder
AU2019307959B2 (en) 2018-07-20 2025-09-25 Momenta Pharmaceuticals, Inc. FcRn antibody compositions
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN115485289A (zh) 2020-03-11 2022-12-16 宾夕法尼亚大学董事会 使用工程化的病毒颗粒进行基因递送的方法和组合物
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN115215939B (zh) 2021-04-14 2025-09-23 中山大学 一种融合蛋白及其制备方法与应用
EP4366772A4 (en) * 2021-07-07 2025-05-21 Singh Biotechnology, LLC SUPPRESSION OF UVEITIS BY SINGLE-DOMAIN ANTIBODIES
EP4392459A4 (en) * 2021-08-27 2026-03-18 Singh Biotechnology Llc SINGLE-DOMAIN THERAPEUTIC ANTIBODY
CA3239267A1 (en) 2021-12-15 2023-06-22 Ronnie M. RUSSELL Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2024003873A1 (en) * 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
AU2023314605A1 (en) 2022-07-25 2025-01-09 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
IL322228A (en) 2023-02-04 2025-09-01 Momenta Pharmaceuticals Inc Compositions and methods for treating hemolytic disease of the fetus and newborn
WO2025004683A1 (ja) * 2023-06-30 2025-01-02 国立大学法人大阪大学 がん検査方法及びがん治療剤
WO2025027511A1 (en) 2023-07-30 2025-02-06 Janssen Biotech, Inc. Molecules that bind to mutant calreticulin and uses thereof
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
TW202540161A (zh) 2023-11-21 2025-10-16 美商健生生物科技公司 治療骨髓增生性腫瘤之方法
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia
WO2025257810A1 (en) * 2024-06-14 2025-12-18 Singh Biotechnology, Llc Suppression of neurodegenerative diseases by single domain antibody

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
ATE348175T1 (de) * 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
AU6234700A (en) 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
DE10019157A1 (de) 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040052762A1 (en) 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
CA2433227A1 (en) * 2000-12-29 2002-08-01 Bio-Technology General, Inc. Specific human antibodies for selective cancer therapy
AU2003219277A1 (en) * 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2008070363A2 (en) 2006-10-31 2008-06-12 Domantis Limited Intrabodies
CA2588106A1 (en) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Single-domain antibodies and heavy chain antibody against egfr and uses thereof
EP2008666A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
US20110195509A1 (en) 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
CN102137658A (zh) * 2008-06-30 2011-07-27 斯兰斯德有限公司 局部递送药物的方法、组合物和系统
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011163423A2 (en) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
US9879093B2 (en) * 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
CN104755621A (zh) * 2012-10-31 2015-07-01 埃西斯药品公司 癌症治疗
EP2970392B1 (en) * 2013-03-15 2019-07-10 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
WO2014153495A2 (en) * 2013-03-22 2014-09-25 University Of Hawaii Novel stat3 inhibitors
CN103368197B (zh) 2013-07-15 2015-11-25 国家电网公司 模块化多电平换流器的阀基控制设备和方法
JP6736464B2 (ja) 2013-08-29 2020-08-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 細胞透過性コンジュゲート及びその使用の方法
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
HUE057605T2 (hu) 2014-10-23 2022-06-28 Singh Molecular Medicine Llc Intracelluláris antigének ellen irányuló egydoménes antitestek

Also Published As

Publication number Publication date
PT3209685T (pt) 2019-06-27
US20160115248A1 (en) 2016-04-28
CA2962275A1 (en) 2016-04-28
ES2900253T3 (es) 2022-03-16
EP3590962B1 (en) 2021-09-29
EP3209685B1 (en) 2019-04-24
BR122020006918B8 (pt) 2023-01-31
IL250961B (en) 2022-02-01
JP2022037002A (ja) 2022-03-08
LT3209685T (lt) 2019-08-26
PT3590962T (pt) 2021-12-15
KR101831123B1 (ko) 2018-02-22
EP3209685A4 (en) 2018-01-24
EP3209685A2 (en) 2017-08-30
AU2015335600A1 (en) 2017-03-16
SI3209685T1 (sl) 2019-10-30
IL289769B2 (en) 2024-05-01
BR112017008165B8 (pt) 2023-01-31
CA3114318A1 (en) 2016-04-28
JP2020015732A (ja) 2020-01-30
CN106852148A (zh) 2017-06-13
JP2017538671A (ja) 2017-12-28
BR122020006914B1 (pt) 2022-03-22
CA3052777A1 (en) 2016-04-28
DK3590962T3 (da) 2021-12-13
JP2021165278A (ja) 2021-10-14
KR102207382B1 (ko) 2021-01-27
JP2019142885A (ja) 2019-08-29
HRP20211889T1 (hr) 2022-03-04
JP6670963B2 (ja) 2020-03-25
MX2017003268A (es) 2017-08-02
US9663570B2 (en) 2017-05-30
BR112017008165B1 (pt) 2020-04-22
KR102207381B1 (ko) 2021-01-27
SMT201900413T1 (it) 2019-09-09
CN111848793A (zh) 2020-10-30
HUE047601T2 (hu) 2020-05-28
MX379450B (es) 2025-03-11
BR122020006914B8 (pt) 2023-01-31
MX2021001098A (es) 2021-03-31
KR20170070002A (ko) 2017-06-21
JP6928773B2 (ja) 2021-09-01
ES2731876T3 (es) 2019-11-19
SMT202100695T1 (it) 2022-01-10
CN111848793B (zh) 2023-08-18
LT3590962T (lt) 2021-12-27
BR122020006918B1 (pt) 2022-03-15
CN106852148B (zh) 2020-07-31
RS62694B1 (sr) 2022-01-31
JP6986180B2 (ja) 2021-12-22
AU2015335600B2 (en) 2019-04-04
US20160115226A1 (en) 2016-04-28
US20160115244A1 (en) 2016-04-28
CA2962275C (en) 2019-11-05
US20160115247A1 (en) 2016-04-28
DK3209685T3 (da) 2019-07-29
US9695234B2 (en) 2017-07-04
EP4006052A1 (en) 2022-06-01
RS59063B1 (sr) 2019-08-30
JP7195400B2 (ja) 2022-12-23
AU2021200416A1 (en) 2021-02-25
KR102023289B1 (ko) 2019-09-19
CY1124867T1 (el) 2022-11-25
KR20180021205A (ko) 2018-02-28
KR20190107199A (ko) 2019-09-18
CA3052777C (en) 2021-06-01
BR122020006907B8 (pt) 2023-01-31
KR20190108646A (ko) 2019-09-24
AU2019204614A1 (en) 2019-07-18
US9546211B2 (en) 2017-01-17
IL289769B1 (en) 2024-01-01
IL289769A (en) 2022-03-01
TW201615834A (zh) 2016-05-01
PL3209685T3 (pl) 2020-01-31
AU2021200416B2 (en) 2022-06-09
IL250961A0 (en) 2017-04-30
PL3590962T3 (pl) 2022-01-31
TWI664289B (zh) 2019-07-01
HRP20191056T1 (hr) 2019-09-20
BR112017008165A2 (pt) 2018-03-06
HUE057605T2 (hu) 2022-06-28
RU2017116710A (ru) 2018-11-23
BR122020006907B1 (pt) 2022-03-22
WO2016065323A3 (en) 2016-06-16
AU2022204167A1 (en) 2022-06-30
EP3590962A1 (en) 2020-01-08
SI3590962T1 (sl) 2022-02-28
WO2016065323A2 (en) 2016-04-28
AU2019204614B2 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1123274T1 (el) Αντισωματα εναντι-οχ40 και χρησεις αυτων
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
CY1123642T1 (el) Αντισωματα enanti-pd-1
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CY1124096T1 (el) Αντισωματα τα οποια στοχευουν αντιγονο ωριμανσης β-κυτταρων και μεθοδοι χρησης
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1123068T1 (el) Εξουδετερωτικα αnτισωματα εναντι gp120 και χρηση αυτων
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CY1121535T1 (el) Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
CY1122436T1 (el) Αντισωματα εναντι του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egfr)
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
AR106556A1 (es) Anticuerpos de un solo dominio dirigidos contra antígenos extracelulares
EA202091567A1 (ru) Химерные белки мти
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX2019007924A (es) Vacunas contra la influenza.
AR102421A1 (es) Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares
EA201691202A1 (ru) Флагеллин-содержащие белковые наночастицы в качестве платформы для вакцины